<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00180479</url>
  </required_header>
  <id_info>
    <org_study_id>03-360</org_study_id>
    <nct_id>NCT00180479</nct_id>
  </id_info>
  <brief_title>SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)</brief_title>
  <official_title>SPIRIT III: A Clinical Evaluation of the Investigational Device XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) in the Treatment of Subjects With de Novo Native Coronary Artery Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Vascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is divided into 5 arms:

        1. Randomized Clinical Trial (RCT): Prospective, randomized, active-controlled, single
           blind, parallel two-arm multi-center clinical trial in the United States (US) comparing
           XIENCE V® Everolimus Eluting Coronary Stent System (CSS) (2.5, 3.0, 3.5 mm diameter
           stents) to the Food and Drug Administration (FDA) approved commercially available active
           control TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent (TAXUS® EXPRESS2™ PECS)
           System

        2. US 2.25 mm non-randomized arm using 2.25 mm diameter XIENCE V® Everolimus Eluting CSS

        3. US 4.0 mm non-randomized arm using 4.0 mm diameter XIENCE V® Everolimus Eluting CSS

        4. US 38 mm non-randomized arm using 38 mm in length XIENCE V® Everolimus Eluting CSS

        5. Japanese non-randomized arm using XIENCE V® Everolimus Eluting CSS (2.5, 3.0, 3.5, 4.0
           mm diameter stents) in Japan

      The TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System is Manufactured by Boston
      Scientific.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the SPIRIT III clinical trial is to evaluate the safety and efficacy of the
      XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS). The XIENCE V® EECS
      (XIENCE V® arm) will be compared to an active control group represented by the FDA approved
      commercially available Boston Scientific TAXUS® EXPRESS2™ Paclitaxel-Eluting Coronary Stent
      (TAXUS® EXPRESS2™ PECS) System (TAXUS® arm).

      The SPIRIT III clinical trial consists of a randomized clinical trial (RCT) in the US which
      will enroll approximately 1,002 subjects (2:1 randomization XIENCE V® EECS : TAXUS® EXPRESS2™
      PECS) with a maximum of two de novo native coronary artery lesion treatment within vessel
      sizes &gt;= 2.5 mm and &lt;= 3.75 mm.

      The SPIRIT III clinical trial also consists of three concurrent US non-randomized arms (2.25
      mm diameter stent, 4.0 mm diameter stent and 38 mm length stent arms) and one Japanese
      non-randomized arm as follows:

        1. 105 subjects with a maximum of two de novo native coronary artery lesion within vessel
           sizes &gt; 2.25 mm and &lt; 2.5 mm and lesion length &lt;= 22 mm will be enrolled concurrently in
           the US 2.25 mm non-randomized treatment arm

        2. 80 subjects with a maximum of two de novo native coronary artery lesion within vessel
           sizes &gt; 3.75 mm and &gt;= 4.25 mm and lesion length &lt;= 28 mm will be enrolled concurrently
           in the US 4.0 mm non-randomized treatment arm

        3. 105 subjects with a maximum of two de novo native coronary artery lesion within vessel
           sizes &gt; 3.0 mm and &lt; 4.25 mm and lesion length &gt; 24 mm and &lt; 32 mm will be enrolled
           concurrently in the US 38 mm non-randomized treatment arm.

        4. 88 Japanese subjects with a maximum of two de novo native coronary artery lesions within
           vessel sizes &gt;= 2.5 mm and &lt;= 4.25 mm and lesion length &lt;= 28 mm will be enrolled
           concurrently in the non-randomized Japanese arm.

      All subjects in the RCT and the four non-randomized arms will be screened per the protocol
      required inclusion/exclusion criteria. The data collected will be compared to data from the
      subjects enrolled into the TAXUS® arm of US RCT.

      Subjects enrolled in the US RCT will be sub-grouped based on whether they will have an
      angiographic and/or an intravascular ultrasound (IVUS) follow-up at 240 days as follows:

      Group A: Angiographic and IVUS follow-up at 240 days (N=240) Group B: Angiographic follow-up
      at 240 days (N=324) Group C: No angiographic or IVUS follow-up (N=438)

      All subjects will have clinical follow-up at 30, 180, 240 and 270 days (Data collected
      through 270 days will be submitted as the primary data set for US and Japanese market
      approval), and 1, 2, 3, 4, and 5 years (for annual reports).

      All subjects enrolled into three US non-randomized arms (N=105 for 2.25 mm arm, N=80 for 4.0
      mm arm and N=105 for 38 mm stent arm) will have clinical follow-up at 30, 180, 240, and 270
      days, and angiographic follow-up at 240 days. No IVUS follow-up is required for subjects
      enrolled in these arms.

      All subjects enrolled into the Japanese non-randomized arm (N=88) will have clinical
      follow-up at 30, 180, 240, and 270 days, and angiographic and IVUS follow-up at 240 days.

      All subjects who receive a bailout stent will be assigned to Group A follow-up subgroup
      (angiographic and IVUS follow-up at 240 days after the index procedure), regardless of their
      primary assignment at randomization. At sites without IVUS capability, subjects receiving
      bailout stent will be assigned to Group B follow-up subgroup (angiographic follow-up at 240
      days after the index procedure). Angiographic follow-up is required for all bailout subjects
      at 240 days.

      Data from the US RCT will be submitted to the FDA as the primary data set for product
      approval for RVD &gt;= 2.5 mm and &lt;= 3.75 mm (2.5 mm, 3.0 mm and 3.5 mm stents). Combined data
      of the US trial/Japanese non-randomized arm will be submitted to the Japanese Ministry of
      Health, Labor and Welfare (MHLW) for Japanese approval for RVD&gt;=2.5 mm and &lt;= 4.25 mm (2.5
      mm, 3.0 mm 3.5 mm and 4.0 mm stents). Data from the Japanese non-randomized arm will be
      submitted to the FDA as additional safety data. Data from the US non-randomized arms of the
      trial will be the primary data sets for approval for 2.25 mm diameter stent (RVD &gt; 2.25 mm
      and &lt; 2.5 mm), 4.0 mm diameter stent (RVD &gt; 3.75 mm and &lt;= 4.25 mm) and 38 mm length stent
      (RVD &gt; 3.0 mm and &lt;= 4.25 mm and lesion length &gt; 24 mm and &lt;= 32 mm), respectively in the US.

      A pharmacokinetic substudy will be carried out in a minimum of 5 pre-determined sites in the
      US and a minimum of 5 pre-determined sites in Japan. In the US, the pharmacokinetics (PK) of
      everolimus, as delivered by the XIENCE V® EECS will be analyzed in a subset of 15 subjects
      (minimum) with single vessel/lesion treatment, and up to 20 subjects with dual vessel/lesion
      treatment, respectively. In Japan, a minimum of 10 subjects with single vessel/lesion
      treatment and up to 20 subjects with dual vessel/lesion treatment will have a PK measurements
      performed. These subsets will include subjects receiving overlapping stents.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Endpoint: In-segment Late Loss (LL)</measure>
    <time_frame>240 days</time_frame>
    <description>In-segment minimal lumen diameter (MLD) post-procedure minus (-) in segment MLD at 240 day follow-up and 5 mm proximal and 5mm distal to the stent equals Late Loss. MLD defined: The average of two orthogonal views (when possible) of the narrowest point within the area of assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Secondary Endpoint: Ischemia Driven Target Vessel Failure (ID-TVF)</measure>
    <time_frame>270 days</time_frame>
    <description>The composite endpoint comprised of:
Cardiac death (death in which a cardiac cause cannot be excluded)
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI
Ischemia-driven target vessel revascularization (TVR) by CABG or PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Failure (TVF)</measure>
    <time_frame>30 days</time_frame>
    <description>The composite endpoint comprised of:
Cardiac death (death in which a cardiac cause cannot be excluded)
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI
Ischemia-driven target vessel revascularization (TVR) by CABG or PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Failure (TVF)</measure>
    <time_frame>180 days</time_frame>
    <description>The composite endpoint comprised of:
Cardiac death (death in which a cardiac cause cannot be excluded)
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI
Ischemia-driven target vessel revascularization (TVR) by CABG or PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Failure (TVF)</measure>
    <time_frame>1 year</time_frame>
    <description>The composite endpoint comprised of:
Cardiac death (death in which a cardiac cause cannot be excluded)
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI
Ischemia-driven target vessel revascularization (TVR) by CABG or PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Failure (TVF)</measure>
    <time_frame>2 year</time_frame>
    <description>The composite endpoint comprised of:
Cardiac death (death in which a cardiac cause cannot be excluded)
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI
Ischemia-driven target vessel revascularization (TVR) by CABG or PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Failure (TVF)</measure>
    <time_frame>3 year</time_frame>
    <description>The composite endpoint comprised of:
Cardiac death (death in which a cardiac cause cannot be excluded)
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI
Ischemia-driven target vessel revascularization (TVR) by CABG or PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Failure (TVF)</measure>
    <time_frame>4 year</time_frame>
    <description>The composite endpoint comprised of:
Cardiac death (death in which a cardiac cause cannot be excluded)
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI
Ischemia-driven target vessel revascularization (TVR) by CABG or PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Target Lesion Revascularization (ID-TLR)</measure>
    <time_frame>30 days</time_frame>
    <description>Revascularization @ target lesion associated w/ any of following:
(+) functional ischemia study Ischemic symptoms &amp; angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Target Lesion Revascularization (ID-TLR)</measure>
    <time_frame>180 days</time_frame>
    <description>Revascularization @ target lesion associated w/ any of following:
(+) functional ischemia study Ischemic symptoms &amp; angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Target Lesion Revascularization (ID-TLR)</measure>
    <time_frame>270 days</time_frame>
    <description>Revascularization @ target lesion associated w/ any of following:
(+) functional ischemia study Ischemic symptoms &amp; angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Target Lesion Revascularization (ID-TLR)</measure>
    <time_frame>1 years</time_frame>
    <description>Revascularization @ target lesion associated w/ any of following:
(+) functional ischemia study Ischemic symptoms &amp; angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Target Lesion Revascularization (ID-TLR)</measure>
    <time_frame>2 years</time_frame>
    <description>Revascularization @ target lesion associated w/ any of following:
(+) functional ischemia study Ischemic symptoms &amp; angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Target Lesion Revascularization (ID-TLR)</measure>
    <time_frame>3 year</time_frame>
    <description>Revascularization @ target lesion associated w/ any of following:
(+) functional ischemia study Ischemic symptoms &amp; angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Target Lesion Revascularization (ID-TLR)</measure>
    <time_frame>4 year</time_frame>
    <description>Revascularization @ target lesion associated w/ any of following:
(+) functional ischemia study Ischemic symptoms &amp; angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Target Vessel Revascularization (ID-TVR)</measure>
    <time_frame>30 days</time_frame>
    <description>Revascularization at the target vessel associated with any of the following
Positive functional ischemia study
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study
Derived from Non-Hierarchical Subject Counts of Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Target Vessel Revascularization (ID-TVR)</measure>
    <time_frame>180 days</time_frame>
    <description>Revascularization at the target vessel associated with any of the following
Positive functional ischemia study
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study
Derived from Non-Hierarchical Subject Counts of Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Target Vessel Revascularization (ID-TVR)</measure>
    <time_frame>270 days</time_frame>
    <description>Revascularization at the target vessel associated with any of the following
Positive functional ischemia study
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study
Derived from Non-Hierarchical Subject Counts of Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Target Vessel Revascularization (ID-TVR)</measure>
    <time_frame>1 year</time_frame>
    <description>Revascularization at the target vessel associated with any of the following
Positive functional ischemia study
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study
Derived from Non-Hierarchical Subject Counts of Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Target Vessel Revascularization (ID-TVR)</measure>
    <time_frame>2 years</time_frame>
    <description>Revascularization at the target vessel associated with any of the following
Positive functional ischemia study
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study
Derived from Non-Hierarchical Subject Counts of Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Target Vessel Revascularization (ID-TVR)</measure>
    <time_frame>3 years</time_frame>
    <description>Revascularization at the target vessel associated with any of the following
Positive functional ischemia study
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study
Derived from Non-Hierarchical Subject Counts of Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Target Vessel Revascularization (ID-TVR)</measure>
    <time_frame>4 years</time_frame>
    <description>Revascularization at the target vessel associated with any of the following
Positive functional ischemia study
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study
Derived from Non-Hierarchical Subject Counts of Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Major Adverse Cardiac Event (MACE)</measure>
    <time_frame>30 days</time_frame>
    <description>The composite endpoint comprised of:
Cardiac death
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Major Adverse Cardiac Event (MACE)</measure>
    <time_frame>180 days</time_frame>
    <description>The composite endpoint comprised of:
Cardiac death
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Major Adverse Cardiac Event (MACE)</measure>
    <time_frame>270 days</time_frame>
    <description>The composite endpoint comprised of:
Cardiac death
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Major Adverse Cardiac Event (MACE)</measure>
    <time_frame>1 year</time_frame>
    <description>The composite endpoint comprised of:
Cardiac death
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Major Adverse Cardiac Event(MACE)</measure>
    <time_frame>2 years</time_frame>
    <description>The composite endpoint comprised of:
Cardiac death
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Major Adverse Cardiac Event (MACE)</measure>
    <time_frame>3 year</time_frame>
    <description>The composite endpoint comprised of:
Cardiac death
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Major Adverse Cardiac Event (MACE)</measure>
    <time_frame>4 year</time_frame>
    <description>The composite endpoint comprised of:
Cardiac death
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent % Angiographic Binary Restenosis (% ABR) Rate</measure>
    <time_frame>at 240 days</time_frame>
    <description>Percent of subjects with a follow-up in-stent percent diameter stenosis of ≥ 50% per quantitative coronary angiography (QCA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-segment % Angiographic Binary Restenosis (% ABR) Rate</measure>
    <time_frame>240 days</time_frame>
    <description>Percent of subjects with a follow-up in-segment percent diameter stenosis of ≥ 50% per QCA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persisting Incomplete Stent Apposition, Late-acquired Incomplete Stent Apposition, Aneurysm, Thrombosis, and Persisting Dissection</measure>
    <time_frame>at 240 days</time_frame>
    <description>Incomplete Apposition (Persisting &amp; Late acquired): Failure to completely appose vessel wall w/ ≥1 strut separated from vessel wall w/ blood behind strut per ultrasound. Aneurysm: Abnormal vessel expansion ≥ 1.5 of reference vessel diameter. Thrombus: Protocol &amp; ARC definition.
Persisting dissection @ follow-up, present post-procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Success: Clinical Device</measure>
    <time_frame>In-hospital</time_frame>
    <description>Successful delivery and deployment of 1st implanted study stent/s @ the intended target lesion and successful withdrawal of the stent delivery system with final residual stenosis &lt; 50%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Success: Clinical Procedure</measure>
    <time_frame>In-hospital</time_frame>
    <description>Successful delivery and deployment of study stent/s @ the intended target lesion and successful withdrawal of the stent delivery system with final residual stenosis &lt; 50%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proximal Late Loss</measure>
    <time_frame>at 240 days</time_frame>
    <description>Proximal Minimum Lumen Diameter (MLD) post-procedure minus proximal MLD at follow-up (proximal defined as within 5 mm of healthy tissue proximal to stent placement)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distal Late Loss</measure>
    <time_frame>240 days</time_frame>
    <description>Distal MLD post-procedure minus distal MLD at follow-up (distal defined as within 5 mm of healthy tissue distal to stent placement)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent Late Loss</measure>
    <time_frame>at 240 days</time_frame>
    <description>In-stent MLD post-procedure minus in-stent MLD at follow-up (in-stent defined as within the margins of the stent)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% Volume Obstruction (% VO)</measure>
    <time_frame>at 240 days</time_frame>
    <description>Defined as stent intimal hyperplasia and calculated as 100*(Stent Volume - Lumen Volume)/Stent Volume by IVUS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent % Diameter Stenosis (% DS)</measure>
    <time_frame>at 240 days</time_frame>
    <description>In-stent: Within the margins of the stent, the value calculated as 100 * (1 - in-stent MLD/RVD) using the mean values from two orthogonal views (when possible) by QCA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-segment % Diameter Stenosis (% DS)</measure>
    <time_frame>240 days</time_frame>
    <description>Within the margins of the stent, 5 mm proximal and 5 mm distal to the stent, the value calculated as 100 * (1 - in-segment MLD/RVD) using the mean values from two orthogonal views (when possible) by QCA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Failure (TVF)</measure>
    <time_frame>5 years</time_frame>
    <description>The composite endpoint comprised of:
Cardiac death (death in which a cardiac cause cannot be excluded)
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI
Ischemia-driven target vessel revascularization (TVR) by CABG or PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Target Lesion Revascularization (ID-TLR)</measure>
    <time_frame>5 years</time_frame>
    <description>Revascularization @ target lesion associated w/ any of following:
(+) functional ischemia study Ischemic symptoms &amp; angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Target Vessel Revascularization (ID-TVR)</measure>
    <time_frame>5 years</time_frame>
    <description>Revascularization at the target vessel associated with any of the following
Positive functional ischemia study
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study
Derived from Non-Hierarchical Subject Counts of Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Major Adverse Cardiac Event (MACE)</measure>
    <time_frame>5 years</time_frame>
    <description>The composite endpoint comprised of:
Cardiac death
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1002</enrollment>
  <condition>Stents</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Total Coronary Occlusion</condition>
  <condition>Coronary Artery Restenosis</condition>
  <condition>Stent Thrombosis</condition>
  <condition>Vascular Disease</condition>
  <condition>Myocardial Ischemia</condition>
  <condition>Coronary Artery Stenosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TAXUS® EXPRESS2™Paclitaxel Eluting Coronary Stent System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>XIENCE V® Everolimus Eluting Coronary Stent</intervention_name>
    <description>Drug eluting stent implantation stent in the treatment of coronary artery disease.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>XIENCE V® Everolimus Eluting Coronary Stent System</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent</intervention_name>
    <description>Drug eluting stent implantation stent in the treatment of coronary artery disease.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Target lesion(s) must be located in a native epicardial vessel with visually estimated
             diameter between &gt;= 2.25 mm and &lt;= 4.25 mm and a lesion length &lt;= 32 mm

          -  The target lesion(s) must be in a major artery or branch with a visually estimated
             stenosis of &gt;= 50% and &lt; 100% with a thrombolysis in myocardial infarction (TIMI) flow
             of &gt;= 1

          -  Non-study, percutaneous intervention for lesions in a non-target vessel is allowed if
             done &gt;= 90 days prior to the index procedure (subjects who received brachytherapy will
             be excluded from the trial)

        Exclusion Criteria:

          -  Located within an arterial or saphenous vein graft or distal to a diseased (vessel
             irregularity per angiogram and &gt; 20% stenosed lesion by visual estimation) arterial or
             saphenous vein graft

          -  Lesion involving a bifurcation &gt;= 2 mm in diameter or ostial lesion &gt; 50% stenosed by
             visual estimation or side branch requiring predilatation

          -  Located in a major epicardial vessel that has been previously treated with
             brachytherapy

          -  Located in a major epicardial vessel that has been previously treated with
             percutaneous intervention &lt; 9 months prior to index procedure

          -  Total occlusion (TIMI flow 0), prior to wire passing

          -  The target vessel contains thrombus

          -  Another significant lesion (&gt; 40% diameter stenosis [DS]) is located in the same
             epicardial vessel as the target lesion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregg W Stone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baptist Medical Center Princeton</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Health System - Montclair</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Heart Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Memorial Hospital</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alta Bates Summit Medical Center</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy General Hospital</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poudre Valley Hospital</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80528</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Cross Medical Center (prev. North Ridge MC)</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Hospital of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Crawford Long Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Joseph's Hospital of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elmhurst Memorial Hospital</name>
      <address>
        <city>Elmhurst</city>
        <state>Illinois</state>
        <zip>60148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John's Hospital</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Heart Center of IN, LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Adventist Hospital</name>
      <address>
        <city>Takoma Park</city>
        <state>Maryland</state>
        <zip>20912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Medical Center</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St John Hospital &amp; Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spectrum Health Hospital</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borgess Medical Center</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Michigan Hospital</name>
      <address>
        <city>Petoskey</city>
        <state>Michigan</state>
        <zip>49770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abbott Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Mississippi Medical Center</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barnes Jewish Hospital</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Patrick Hospital</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Heart Hospital</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Valley Hospital</name>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <zip>07450</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presbyterian Hospital</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island Jewish Medical Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital Health Center</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presbyterian Hospital</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Medical Center</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverside Methodist Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EMH Regional Medical Center</name>
      <address>
        <city>Elyria</city>
        <state>Ohio</state>
        <zip>44035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integris Baptist Medical, Inc.</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sacred Heart Medical Center</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence St. Vincent Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinnacle Health @ Harrisburg Hospital</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Miriam Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Hospital of Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical City Dallas Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TexSan Heart Hospital</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fletcher Allen Health Care</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Mahaffey KW, Cutlip DE, Fitzgerald PJ, Sood P, Su X, Lansky AJ; SPIRIT III Investigators. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA. 2008 Apr 23;299(16):1903-13. doi: 10.1001/jama.299.16.1903.</citation>
    <PMID>18430909</PMID>
  </results_reference>
  <results_reference>
    <citation>Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Caputo R, Xenopoulos N, Applegate R, Gordon P, White RM, Sudhir K, Cutlip DE, Petersen JL; SPIRIT III Investigators. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. Circulation. 2009 Feb 10;119(5):680-6. doi: 10.1161/CIRCULATIONAHA.108.803528. Epub 2009 Jan 26.</citation>
    <PMID>19171853</PMID>
  </results_reference>
  <results_reference>
    <citation>Lansky AJ, Ng VG, Mutlu H, Cristea E, Guiran JB, Midei M, Newman W, Sanz M, Sood P, Doostzadeh J, Su X, White R, Cao S, Sudhir K, Stone GW. Gender-based evaluation of the XIENCE V everolimus-eluting coronary stent system: clinical and angiographic results from the SPIRIT III randomized trial. Catheter Cardiovasc Interv. 2009 Nov 1;74(5):719-27. doi: 10.1002/ccd.22067.</citation>
    <PMID>19530147</PMID>
  </results_reference>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <results_first_submitted>October 15, 2008</results_first_submitted>
  <results_first_submitted_qc>December 11, 2008</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 15, 2008</results_first_posted>
  <last_update_submitted>November 16, 2011</last_update_submitted>
  <last_update_submitted_qc>November 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Everolimus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
    <mesh_term>Coronary Occlusion</mesh_term>
    <mesh_term>Coronary Restenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>1002 subjects were recruited at 65 sites. Eligible subjects invited to participate either in-hospital or in-clinic prior to first procedure and required to provide signed informed consent prior to enrollment. Final eligibility based on angiogram before the intended procedure. Dates of recruitment: 6/22/05 through 3/15/06.</recruitment_details>
      <pre_assignment_details>Subjects were randomized via telephone randomization and stratified by single and dual lesion/vessel treatment, diabetes mellitus status, and study sites. Randomization only occurred after verification of the inclusion/exclusion criteria and successful pre-dilatation. See the Eligibility Criteria (inclusion/exclusion criteria) for details.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>XIENCE V® EECSS</title>
          <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
        </group>
        <group group_id="P2">
          <title>TAXUS® EXPRESS2™ ECSS</title>
          <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="669"/>
                <participants group_id="P2" count="333">1 patient randomized never signed consent, therefore no data collected. Analysis group = 332.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="653"/>
                <participants group_id="P2" count="320"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Informed consent not signed</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>XIENCE V® EECSS</title>
          <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
        </group>
        <group group_id="B2">
          <title>TAXUS® EXPRESS2™ ECSS</title>
          <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="669"/>
            <count group_id="B2" value="333"/>
            <count group_id="B3" value="1002"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="376"/>
                    <measurement group_id="B2" value="191"/>
                    <measurement group_id="B3" value="567"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="293"/>
                    <measurement group_id="B2" value="141"/>
                    <measurement group_id="B3" value="434"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.23" spread="10.53"/>
                    <measurement group_id="B2" value="62.80" spread="10.24"/>
                    <measurement group_id="B3" value="63.08" spread="10.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="200"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="469"/>
                    <measurement group_id="B2" value="218"/>
                    <measurement group_id="B3" value="687"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="669"/>
                    <measurement group_id="B2" value="333"/>
                    <measurement group_id="B3" value="1002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Primary Endpoint: In-segment Late Loss (LL)</title>
        <description>In-segment minimal lumen diameter (MLD) post-procedure minus (–) in segment MLD at 240 day follow-up and 5 mm proximal and 5mm distal to the stent equals Late Loss. MLD defined: The average of two orthogonal views (when possible) of the narrowest point within the area of assessment.</description>
        <time_frame>240 days</time_frame>
        <population>Only a certain number of patients were required to have angiographic follow-up to provide this endpoint information.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V® EECSS</title>
            <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® EXPRESS2™ ECSS</title>
            <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Endpoint: In-segment Late Loss (LL)</title>
          <description>In-segment minimal lumen diameter (MLD) post-procedure minus (–) in segment MLD at 240 day follow-up and 5 mm proximal and 5mm distal to the stent equals Late Loss. MLD defined: The average of two orthogonal views (when possible) of the narrowest point within the area of assessment.</description>
          <population>Only a certain number of patients were required to have angiographic follow-up to provide this endpoint information.</population>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="301"/>
                <count group_id="O2" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.41"/>
                    <measurement group_id="O2" value="0.28" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Primary endpoint analyzed for intent-to-treat &amp; per-treatment evaluable pop. Hypothesis test based on per-subject analysis of intent-to-treat pop. using analysis lesion. The null hypothesis evaluated using non-inferiority test with asymptotic test statistic.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Sample size calculation for endpoint of in-segment LL at 240 days is based on these assumptions: one-tailed non-inferiority= (δ)=0.025, Power=99%, Randomization ratio 2:1, True mean in-seg. LL is assumed to be 0.24 mm in both arms.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Secondary Endpoint: Ischemia Driven Target Vessel Failure (ID-TVF)</title>
        <description>The composite endpoint comprised of:
Cardiac death (death in which a cardiac cause cannot be excluded)
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI
Ischemia-driven target vessel revascularization (TVR) by CABG or PCI</description>
        <time_frame>270 days</time_frame>
        <population>All patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V® EECSS</title>
            <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® EXPRESS2™ ECSS</title>
            <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          </group>
        </group_list>
        <measure>
          <title>Major Secondary Endpoint: Ischemia Driven Target Vessel Failure (ID-TVF)</title>
          <description>The composite endpoint comprised of:
Cardiac death (death in which a cardiac cause cannot be excluded)
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI
Ischemia-driven target vessel revascularization (TVR) by CABG or PCI</description>
          <population>All patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="657"/>
                <count group_id="O2" value="321"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2"/>
                    <measurement group_id="O2" value="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis was evaluated using a non-inferiority Z statistic. Non-inferiority was defined as a one-sided alpha of 0.05 and a difference in TVF rate of no more than 5.5%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Study had 89% statistical power based on major secondary endpoint to prove non-inferiority of XIENCE® V to TAXUS®, non-inferiority delta=5.5%, true TVF rate 9.4% in both arms with overall 5% alpha (one-sided), assuming 1% subject dropout rate.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Failure (TVF)</title>
        <description>The composite endpoint comprised of:
Cardiac death (death in which a cardiac cause cannot be excluded)
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI
Ischemia-driven target vessel revascularization (TVR) by CABG or PCI</description>
        <time_frame>30 days</time_frame>
        <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V® EECSS</title>
            <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® EXPRESS2™ ECSS</title>
            <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Failure (TVF)</title>
          <description>The composite endpoint comprised of:
Cardiac death (death in which a cardiac cause cannot be excluded)
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI
Ischemia-driven target vessel revascularization (TVR) by CABG or PCI</description>
          <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="667"/>
                <count group_id="O2" value="330"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Failure (TVF)</title>
        <description>The composite endpoint comprised of:
Cardiac death (death in which a cardiac cause cannot be excluded)
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI
Ischemia-driven target vessel revascularization (TVR) by CABG or PCI</description>
        <time_frame>180 days</time_frame>
        <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V® EECSS</title>
            <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® EXPRESS2™ ECSS</title>
            <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Failure (TVF)</title>
          <description>The composite endpoint comprised of:
Cardiac death (death in which a cardiac cause cannot be excluded)
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI
Ischemia-driven target vessel revascularization (TVR) by CABG or PCI</description>
          <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="664"/>
                <count group_id="O2" value="326"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1"/>
                    <measurement group_id="O2" value="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Failure (TVF)</title>
        <description>The composite endpoint comprised of:
Cardiac death (death in which a cardiac cause cannot be excluded)
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI
Ischemia-driven target vessel revascularization (TVR) by CABG or PCI</description>
        <time_frame>1 year</time_frame>
        <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V® EECSS</title>
            <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® EXPRESS2™ ECSS</title>
            <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Failure (TVF)</title>
          <description>The composite endpoint comprised of:
Cardiac death (death in which a cardiac cause cannot be excluded)
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI
Ischemia-driven target vessel revascularization (TVR) by CABG or PCI</description>
          <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="654"/>
                <count group_id="O2" value="319"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6"/>
                    <measurement group_id="O2" value="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Failure (TVF)</title>
        <description>The composite endpoint comprised of:
Cardiac death (death in which a cardiac cause cannot be excluded)
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI
Ischemia-driven target vessel revascularization (TVR) by CABG or PCI</description>
        <time_frame>2 year</time_frame>
        <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V® EECSS</title>
            <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® EXPRESS2™ ECSS</title>
            <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Failure (TVF)</title>
          <description>The composite endpoint comprised of:
Cardiac death (death in which a cardiac cause cannot be excluded)
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI
Ischemia-driven target vessel revascularization (TVR) by CABG or PCI</description>
          <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="637"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3"/>
                    <measurement group_id="O2" value="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Failure (TVF)</title>
        <description>The composite endpoint comprised of:
Cardiac death (death in which a cardiac cause cannot be excluded)
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI
Ischemia-driven target vessel revascularization (TVR) by CABG or PCI</description>
        <time_frame>3 year</time_frame>
        <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V® EECSS</title>
            <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® EXPRESS2™ ECSS</title>
            <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Failure (TVF)</title>
          <description>The composite endpoint comprised of:
Cardiac death (death in which a cardiac cause cannot be excluded)
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI
Ischemia-driven target vessel revascularization (TVR) by CABG or PCI</description>
          <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="629"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3"/>
                    <measurement group_id="O2" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Failure (TVF)</title>
        <description>The composite endpoint comprised of:
Cardiac death (death in which a cardiac cause cannot be excluded)
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI
Ischemia-driven target vessel revascularization (TVR) by CABG or PCI</description>
        <time_frame>4 year</time_frame>
        <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V® EECSS</title>
            <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® EXPRESS2™ ECSS</title>
            <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Failure (TVF)</title>
          <description>The composite endpoint comprised of:
Cardiac death (death in which a cardiac cause cannot be excluded)
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI
Ischemia-driven target vessel revascularization (TVR) by CABG or PCI</description>
          <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="615"/>
                <count group_id="O2" value="302"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5"/>
                    <measurement group_id="O2" value="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Target Lesion Revascularization (ID-TLR)</title>
        <description>Revascularization @ target lesion associated w/ any of following:
(+) functional ischemia study Ischemic symptoms &amp; angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study</description>
        <time_frame>30 days</time_frame>
        <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V® EECSS</title>
            <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® EXPRESS2™ ECSS</title>
            <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Target Lesion Revascularization (ID-TLR)</title>
          <description>Revascularization @ target lesion associated w/ any of following:
(+) functional ischemia study Ischemic symptoms &amp; angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study</description>
          <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="667"/>
                <count group_id="O2" value="330"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Target Lesion Revascularization (ID-TLR)</title>
        <description>Revascularization @ target lesion associated w/ any of following:
(+) functional ischemia study Ischemic symptoms &amp; angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study</description>
        <time_frame>180 days</time_frame>
        <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V® EECSS</title>
            <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® EXPRESS2™ ECSS</title>
            <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Target Lesion Revascularization (ID-TLR)</title>
          <description>Revascularization @ target lesion associated w/ any of following:
(+) functional ischemia study Ischemic symptoms &amp; angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study</description>
          <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="664"/>
                <count group_id="O2" value="326"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Target Lesion Revascularization (ID-TLR)</title>
        <description>Revascularization @ target lesion associated w/ any of following:
(+) functional ischemia study Ischemic symptoms &amp; angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study</description>
        <time_frame>270 days</time_frame>
        <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V® EECSS</title>
            <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® EXPRESS2™ ECSS</title>
            <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Target Lesion Revascularization (ID-TLR)</title>
          <description>Revascularization @ target lesion associated w/ any of following:
(+) functional ischemia study Ischemic symptoms &amp; angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study</description>
          <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="659"/>
                <count group_id="O2" value="320"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7"/>
                    <measurement group_id="O2" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Target Lesion Revascularization (ID-TLR)</title>
        <description>Revascularization @ target lesion associated w/ any of following:
(+) functional ischemia study Ischemic symptoms &amp; angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study</description>
        <time_frame>1 years</time_frame>
        <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V® EECSS</title>
            <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® EXPRESS2™ ECSS</title>
            <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Target Lesion Revascularization (ID-TLR)</title>
          <description>Revascularization @ target lesion associated w/ any of following:
(+) functional ischemia study Ischemic symptoms &amp; angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study</description>
          <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="654"/>
                <count group_id="O2" value="319"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4"/>
                    <measurement group_id="O2" value="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Target Lesion Revascularization (ID-TLR)</title>
        <description>Revascularization @ target lesion associated w/ any of following:
(+) functional ischemia study Ischemic symptoms &amp; angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study</description>
        <time_frame>2 years</time_frame>
        <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V® EECSS</title>
            <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® EXPRESS2™ ECSS</title>
            <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Target Lesion Revascularization (ID-TLR)</title>
          <description>Revascularization @ target lesion associated w/ any of following:
(+) functional ischemia study Ischemic symptoms &amp; angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study</description>
          <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="637"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7"/>
                    <measurement group_id="O2" value="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Target Lesion Revascularization (ID-TLR)</title>
        <description>Revascularization @ target lesion associated w/ any of following:
(+) functional ischemia study Ischemic symptoms &amp; angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study</description>
        <time_frame>3 year</time_frame>
        <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V® EECSS</title>
            <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® EXPRESS2™ ECSS</title>
            <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Target Lesion Revascularization (ID-TLR)</title>
          <description>Revascularization @ target lesion associated w/ any of following:
(+) functional ischemia study Ischemic symptoms &amp; angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study</description>
          <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="629"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7"/>
                    <measurement group_id="O2" value="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Target Lesion Revascularization (ID-TLR)</title>
        <description>Revascularization @ target lesion associated w/ any of following:
(+) functional ischemia study Ischemic symptoms &amp; angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study</description>
        <time_frame>4 year</time_frame>
        <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V® EECSS</title>
            <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® EXPRESS2™ ECSS</title>
            <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Target Lesion Revascularization (ID-TLR)</title>
          <description>Revascularization @ target lesion associated w/ any of following:
(+) functional ischemia study Ischemic symptoms &amp; angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study</description>
          <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="615"/>
                <count group_id="O2" value="302"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0"/>
                    <measurement group_id="O2" value="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Target Vessel Revascularization (ID-TVR)</title>
        <description>Revascularization at the target vessel associated with any of the following
Positive functional ischemia study
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study
Derived from Non-Hierarchical Subject Counts of Adverse Events</description>
        <time_frame>30 days</time_frame>
        <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V® EECSS</title>
            <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® EXPRESS2™ ECSS</title>
            <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Target Vessel Revascularization (ID-TVR)</title>
          <description>Revascularization at the target vessel associated with any of the following
Positive functional ischemia study
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study
Derived from Non-Hierarchical Subject Counts of Adverse Events</description>
          <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="667"/>
                <count group_id="O2" value="330"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                    <measurement group_id="O2" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Target Vessel Revascularization (ID-TVR)</title>
        <description>Revascularization at the target vessel associated with any of the following
Positive functional ischemia study
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study
Derived from Non-Hierarchical Subject Counts of Adverse Events</description>
        <time_frame>180 days</time_frame>
        <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V® EECSS</title>
            <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® EXPRESS2™ ECSS</title>
            <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Target Vessel Revascularization (ID-TVR)</title>
          <description>Revascularization at the target vessel associated with any of the following
Positive functional ischemia study
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study
Derived from Non-Hierarchical Subject Counts of Adverse Events</description>
          <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="664"/>
                <count group_id="O2" value="326"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Target Vessel Revascularization (ID-TVR)</title>
        <description>Revascularization at the target vessel associated with any of the following
Positive functional ischemia study
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study
Derived from Non-Hierarchical Subject Counts of Adverse Events</description>
        <time_frame>270 days</time_frame>
        <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V® EECSS</title>
            <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® EXPRESS2™ ECSS</title>
            <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Target Vessel Revascularization (ID-TVR)</title>
          <description>Revascularization at the target vessel associated with any of the following
Positive functional ischemia study
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study
Derived from Non-Hierarchical Subject Counts of Adverse Events</description>
          <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="659"/>
                <count group_id="O2" value="320"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9"/>
                    <measurement group_id="O2" value="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Target Vessel Revascularization (ID-TVR)</title>
        <description>Revascularization at the target vessel associated with any of the following
Positive functional ischemia study
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study
Derived from Non-Hierarchical Subject Counts of Adverse Events</description>
        <time_frame>1 year</time_frame>
        <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V® EECSS</title>
            <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® EXPRESS2™ ECSS</title>
            <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Target Vessel Revascularization (ID-TVR)</title>
          <description>Revascularization at the target vessel associated with any of the following
Positive functional ischemia study
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study
Derived from Non-Hierarchical Subject Counts of Adverse Events</description>
          <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="654"/>
                <count group_id="O2" value="319"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1"/>
                    <measurement group_id="O2" value="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Target Vessel Revascularization (ID-TVR)</title>
        <description>Revascularization at the target vessel associated with any of the following
Positive functional ischemia study
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study
Derived from Non-Hierarchical Subject Counts of Adverse Events</description>
        <time_frame>2 years</time_frame>
        <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V® EECSS</title>
            <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® EXPRESS2™ ECSS</title>
            <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Target Vessel Revascularization (ID-TVR)</title>
          <description>Revascularization at the target vessel associated with any of the following
Positive functional ischemia study
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study
Derived from Non-Hierarchical Subject Counts of Adverse Events</description>
          <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="637"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9"/>
                    <measurement group_id="O2" value="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Target Vessel Revascularization (ID-TVR)</title>
        <description>Revascularization at the target vessel associated with any of the following
Positive functional ischemia study
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study
Derived from Non-Hierarchical Subject Counts of Adverse Events</description>
        <time_frame>3 years</time_frame>
        <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V® EECSS</title>
            <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® EXPRESS2™ ECSS</title>
            <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Target Vessel Revascularization (ID-TVR)</title>
          <description>Revascularization at the target vessel associated with any of the following
Positive functional ischemia study
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study
Derived from Non-Hierarchical Subject Counts of Adverse Events</description>
          <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="629"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                    <measurement group_id="O2" value="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Target Vessel Revascularization (ID-TVR)</title>
        <description>Revascularization at the target vessel associated with any of the following
Positive functional ischemia study
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study
Derived from Non-Hierarchical Subject Counts of Adverse Events</description>
        <time_frame>4 years</time_frame>
        <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V® EECSS</title>
            <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® EXPRESS2™ ECSS</title>
            <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Target Vessel Revascularization (ID-TVR)</title>
          <description>Revascularization at the target vessel associated with any of the following
Positive functional ischemia study
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study
Derived from Non-Hierarchical Subject Counts of Adverse Events</description>
          <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="615"/>
                <count group_id="O2" value="302"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8"/>
                    <measurement group_id="O2" value="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Major Adverse Cardiac Event (MACE)</title>
        <description>The composite endpoint comprised of:
Cardiac death
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI</description>
        <time_frame>30 days</time_frame>
        <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V® EECSS</title>
            <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® EXPRESS2™ ECSS</title>
            <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Major Adverse Cardiac Event (MACE)</title>
          <description>The composite endpoint comprised of:
Cardiac death
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI</description>
          <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="667"/>
                <count group_id="O2" value="330"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Major Adverse Cardiac Event (MACE)</title>
        <description>The composite endpoint comprised of:
Cardiac death
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI</description>
        <time_frame>180 days</time_frame>
        <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V® EECSS</title>
            <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® EXPRESS2™ ECSS</title>
            <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Major Adverse Cardiac Event (MACE)</title>
          <description>The composite endpoint comprised of:
Cardiac death
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI</description>
          <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="664"/>
                <count group_id="O2" value="326"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9"/>
                    <measurement group_id="O2" value="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Major Adverse Cardiac Event (MACE)</title>
        <description>The composite endpoint comprised of:
Cardiac death
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI</description>
        <time_frame>270 days</time_frame>
        <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V® EECSS</title>
            <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® EXPRESS2™ ECSS</title>
            <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Major Adverse Cardiac Event (MACE)</title>
          <description>The composite endpoint comprised of:
Cardiac death
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI</description>
          <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="659"/>
                <count group_id="O2" value="320"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0"/>
                    <measurement group_id="O2" value="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Major Adverse Cardiac Event (MACE)</title>
        <description>The composite endpoint comprised of:
Cardiac death
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI</description>
        <time_frame>1 year</time_frame>
        <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V® EECSS</title>
            <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® EXPRESS2™ ECSS</title>
            <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Major Adverse Cardiac Event (MACE)</title>
          <description>The composite endpoint comprised of:
Cardiac death
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI</description>
          <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="654"/>
                <count group_id="O2" value="319"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0"/>
                    <measurement group_id="O2" value="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Major Adverse Cardiac Event(MACE)</title>
        <description>The composite endpoint comprised of:
Cardiac death
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI</description>
        <time_frame>2 years</time_frame>
        <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V® EECSS</title>
            <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® EXPRESS2™ ECSS</title>
            <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Major Adverse Cardiac Event(MACE)</title>
          <description>The composite endpoint comprised of:
Cardiac death
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI</description>
          <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="637"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7"/>
                    <measurement group_id="O2" value="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Major Adverse Cardiac Event (MACE)</title>
        <description>The composite endpoint comprised of:
Cardiac death
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI</description>
        <time_frame>3 year</time_frame>
        <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V® EECSS</title>
            <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® EXPRESS2™ ECSS</title>
            <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Major Adverse Cardiac Event (MACE)</title>
          <description>The composite endpoint comprised of:
Cardiac death
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI</description>
          <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="629"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7"/>
                    <measurement group_id="O2" value="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Major Adverse Cardiac Event (MACE)</title>
        <description>The composite endpoint comprised of:
Cardiac death
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI</description>
        <time_frame>4 year</time_frame>
        <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V® EECSS</title>
            <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® EXPRESS2™ ECSS</title>
            <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Major Adverse Cardiac Event (MACE)</title>
          <description>The composite endpoint comprised of:
Cardiac death
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI</description>
          <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="615"/>
                <count group_id="O2" value="302"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8"/>
                    <measurement group_id="O2" value="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In-stent % Angiographic Binary Restenosis (% ABR) Rate</title>
        <description>Percent of subjects with a follow-up in-stent percent diameter stenosis of ≥ 50% per quantitative coronary angiography (QCA)</description>
        <time_frame>at 240 days</time_frame>
        <population>Only a certain number of patients were required to have angiographic or IVUS follow-up. The analysis population for these follow-ups may have changed due to patient's not completing an angiographic or IVUS follow-up procedure. Patients may also have missed the follow-up visits due to early termination from the study.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V® EECSS</title>
            <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® EXPRESS2™ ECSS</title>
            <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          </group>
        </group_list>
        <measure>
          <title>In-stent % Angiographic Binary Restenosis (% ABR) Rate</title>
          <description>Percent of subjects with a follow-up in-stent percent diameter stenosis of ≥ 50% per quantitative coronary angiography (QCA)</description>
          <population>Only a certain number of patients were required to have angiographic or IVUS follow-up. The analysis population for these follow-ups may have changed due to patient's not completing an angiographic or IVUS follow-up procedure. Patients may also have missed the follow-up visits due to early termination from the study.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="343"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3"/>
                    <measurement group_id="O2" value="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In-segment % Angiographic Binary Restenosis (% ABR) Rate</title>
        <description>Percent of subjects with a follow-up in-segment percent diameter stenosis of ≥ 50% per QCA</description>
        <time_frame>240 days</time_frame>
        <population>Only a certain number of patients were required to have angiographic or IVUS follow-up. The analysis population for these follow-ups may have changed due to patient's not completing an angiographic or IVUS follow-up procedure. Patients may also have missed the follow-up visits due to early termination from the study.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V® EECSS</title>
            <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® EXPRESS2™ ECSS</title>
            <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          </group>
        </group_list>
        <measure>
          <title>In-segment % Angiographic Binary Restenosis (% ABR) Rate</title>
          <description>Percent of subjects with a follow-up in-segment percent diameter stenosis of ≥ 50% per QCA</description>
          <population>Only a certain number of patients were required to have angiographic or IVUS follow-up. The analysis population for these follow-ups may have changed due to patient's not completing an angiographic or IVUS follow-up procedure. Patients may also have missed the follow-up visits due to early termination from the study.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="344"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7"/>
                    <measurement group_id="O2" value="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Persisting Incomplete Stent Apposition, Late-acquired Incomplete Stent Apposition, Aneurysm, Thrombosis, and Persisting Dissection</title>
        <description>Incomplete Apposition (Persisting &amp; Late acquired): Failure to completely appose vessel wall w/ ≥1 strut separated from vessel wall w/ blood behind strut per ultrasound. Aneurysm: Abnormal vessel expansion ≥ 1.5 of reference vessel diameter. Thrombus: Protocol &amp; ARC definition.
Persisting dissection @ follow-up, present post-procedure.</description>
        <time_frame>at 240 days</time_frame>
        <population>Only a certain number of patients were required to have angiographic or IVUS follow-up. The analysis population for these follow-ups may have changed due to patient's not completing an angiographic or IVUS follow-up procedure. Patients may also have missed the follow-up visits due to early termination from the study.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V® EECSS</title>
            <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® EXPRESS2™ ECSS</title>
            <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          </group>
        </group_list>
        <measure>
          <title>Persisting Incomplete Stent Apposition, Late-acquired Incomplete Stent Apposition, Aneurysm, Thrombosis, and Persisting Dissection</title>
          <description>Incomplete Apposition (Persisting &amp; Late acquired): Failure to completely appose vessel wall w/ ≥1 strut separated from vessel wall w/ blood behind strut per ultrasound. Aneurysm: Abnormal vessel expansion ≥ 1.5 of reference vessel diameter. Thrombus: Protocol &amp; ARC definition.
Persisting dissection @ follow-up, present post-procedure.</description>
          <population>Only a certain number of patients were required to have angiographic or IVUS follow-up. The analysis population for these follow-ups may have changed due to patient's not completing an angiographic or IVUS follow-up procedure. Patients may also have missed the follow-up visits due to early termination from the study.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.4"/>
                    <measurement group_id="O2" value="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Success: Clinical Device</title>
        <description>Successful delivery and deployment of 1st implanted study stent/s @ the intended target lesion and successful withdrawal of the stent delivery system with final residual stenosis &lt; 50%.</description>
        <time_frame>In-hospital</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V® EECSS</title>
            <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® EXPRESS2™ ECSS</title>
            <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Success: Clinical Device</title>
          <description>Successful delivery and deployment of 1st implanted study stent/s @ the intended target lesion and successful withdrawal of the stent delivery system with final residual stenosis &lt; 50%.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="763"/>
                <count group_id="O2" value="379"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.3"/>
                    <measurement group_id="O2" value="98.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Success: Clinical Procedure</title>
        <description>Successful delivery and deployment of study stent/s @ the intended target lesion and successful withdrawal of the stent delivery system with final residual stenosis &lt; 50%.</description>
        <time_frame>In-hospital</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V® EECSS</title>
            <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® EXPRESS2™ ECSS</title>
            <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Success: Clinical Procedure</title>
          <description>Successful delivery and deployment of study stent/s @ the intended target lesion and successful withdrawal of the stent delivery system with final residual stenosis &lt; 50%.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="661"/>
                <count group_id="O2" value="331"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.5"/>
                    <measurement group_id="O2" value="97.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proximal Late Loss</title>
        <description>Proximal Minimum Lumen Diameter (MLD) post-procedure minus proximal MLD at follow-up (proximal defined as within 5 mm of healthy tissue proximal to stent placement)</description>
        <time_frame>at 240 days</time_frame>
        <population>Only a certain number of patients were required to have angiographic or IVUS follow-up. The analysis population for these follow-ups may have changed due to patient's not completing an angiographic or IVUS follow-up procedure. Patients may also have missed the follow-up visits due to early termination from the study.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V® EECSS</title>
            <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® EXPRESS2™ ECSS</title>
            <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          </group>
        </group_list>
        <measure>
          <title>Proximal Late Loss</title>
          <description>Proximal Minimum Lumen Diameter (MLD) post-procedure minus proximal MLD at follow-up (proximal defined as within 5 mm of healthy tissue proximal to stent placement)</description>
          <population>Only a certain number of patients were required to have angiographic or IVUS follow-up. The analysis population for these follow-ups may have changed due to patient's not completing an angiographic or IVUS follow-up procedure. Patients may also have missed the follow-up visits due to early termination from the study.</population>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="293"/>
                <count group_id="O2" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.40"/>
                    <measurement group_id="O2" value="0.20" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Distal Late Loss</title>
        <description>Distal MLD post-procedure minus distal MLD at follow-up (distal defined as within 5 mm of healthy tissue distal to stent placement)</description>
        <time_frame>240 days</time_frame>
        <population>Only a certain number of patients were required to have angiographic or IVUS follow-up. The analysis population for these follow-ups may have changed due to patient's not completing an angiographic or IVUS follow-up procedure. Patients may also have missed the follow-up visits due to early termination from the study.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V® EECSS</title>
            <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® EXPRESS2™ ECSS</title>
            <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          </group>
        </group_list>
        <measure>
          <title>Distal Late Loss</title>
          <description>Distal MLD post-procedure minus distal MLD at follow-up (distal defined as within 5 mm of healthy tissue distal to stent placement)</description>
          <population>Only a certain number of patients were required to have angiographic or IVUS follow-up. The analysis population for these follow-ups may have changed due to patient's not completing an angiographic or IVUS follow-up procedure. Patients may also have missed the follow-up visits due to early termination from the study.</population>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="327"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.36"/>
                    <measurement group_id="O2" value="0.10" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In-stent Late Loss</title>
        <description>In-stent MLD post-procedure minus in-stent MLD at follow-up (in-stent defined as within the margins of the stent)</description>
        <time_frame>at 240 days</time_frame>
        <population>Only a certain number of patients were required to have angiographic or IVUS follow-up. The analysis population for these follow-ups may have changed due to patient's not completing an angiographic or IVUS follow-up procedure. Patients may also have missed the follow-up visits due to early termination from the study.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V® EECSS</title>
            <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® EXPRESS2™ ECSS</title>
            <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          </group>
        </group_list>
        <measure>
          <title>In-stent Late Loss</title>
          <description>In-stent MLD post-procedure minus in-stent MLD at follow-up (in-stent defined as within the margins of the stent)</description>
          <population>Only a certain number of patients were required to have angiographic or IVUS follow-up. The analysis population for these follow-ups may have changed due to patient's not completing an angiographic or IVUS follow-up procedure. Patients may also have missed the follow-up visits due to early termination from the study.</population>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="342"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.41"/>
                    <measurement group_id="O2" value="0.30" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>% Volume Obstruction (% VO)</title>
        <description>Defined as stent intimal hyperplasia and calculated as 100*(Stent Volume - Lumen Volume)/Stent Volume by IVUS.</description>
        <time_frame>at 240 days</time_frame>
        <population>Only a certain number of patients were required to have angiographic or IVUS follow-up. The analysis population for these follow-ups may have changed due to patient's not completing an angiographic or IVUS follow-up procedure. Patients may also have missed the follow-up visits due to early termination from the study.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V® EECSS</title>
            <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® EXPRESS2™ ECSS</title>
            <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          </group>
        </group_list>
        <measure>
          <title>% Volume Obstruction (% VO)</title>
          <description>Defined as stent intimal hyperplasia and calculated as 100*(Stent Volume - Lumen Volume)/Stent Volume by IVUS.</description>
          <population>Only a certain number of patients were required to have angiographic or IVUS follow-up. The analysis population for these follow-ups may have changed due to patient's not completing an angiographic or IVUS follow-up procedure. Patients may also have missed the follow-up visits due to early termination from the study.</population>
          <units>percent of volume obstruction</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.91" spread="6.35"/>
                    <measurement group_id="O2" value="11.21" spread="9.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In-stent % Diameter Stenosis (% DS)</title>
        <description>In-stent: Within the margins of the stent, the value calculated as 100 * (1 – in-stent MLD/RVD) using the mean values from two orthogonal views (when possible) by QCA.</description>
        <time_frame>at 240 days</time_frame>
        <population>Only a certain number of patients were required to have angiographic or IVUS follow-up. The analysis population for these follow-ups may have changed due to patient's not completing an angiographic or IVUS follow-up procedure. Patients may also have missed the follow-up visits due to early termination from the study.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V® EECSS</title>
            <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® EXPRESS2™ ECSS</title>
            <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          </group>
        </group_list>
        <measure>
          <title>In-stent % Diameter Stenosis (% DS)</title>
          <description>In-stent: Within the margins of the stent, the value calculated as 100 * (1 – in-stent MLD/RVD) using the mean values from two orthogonal views (when possible) by QCA.</description>
          <population>Only a certain number of patients were required to have angiographic or IVUS follow-up. The analysis population for these follow-ups may have changed due to patient's not completing an angiographic or IVUS follow-up procedure. Patients may also have missed the follow-up visits due to early termination from the study.</population>
          <units>percent diameter stenosis</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="343"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.92" spread="16.40"/>
                    <measurement group_id="O2" value="10.30" spread="21.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In-segment % Diameter Stenosis (% DS)</title>
        <description>Within the margins of the stent, 5 mm proximal and 5 mm distal to the stent, the value calculated as 100 * (1 – in-segment MLD/RVD) using the mean values from two orthogonal views (when possible) by QCA.</description>
        <time_frame>240 days</time_frame>
        <population>Only a certain number of patients were required to have angiographic or IVUS follow-up. The analysis population for these follow-ups may have changed due to patient's not completing an angiographic or IVUS follow-up procedure. Patients may also have missed the follow-up visits due to early termination from the study.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V® EECSS</title>
            <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® EXPRESS2™ ECSS</title>
            <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          </group>
        </group_list>
        <measure>
          <title>In-segment % Diameter Stenosis (% DS)</title>
          <description>Within the margins of the stent, 5 mm proximal and 5 mm distal to the stent, the value calculated as 100 * (1 – in-segment MLD/RVD) using the mean values from two orthogonal views (when possible) by QCA.</description>
          <population>Only a certain number of patients were required to have angiographic or IVUS follow-up. The analysis population for these follow-ups may have changed due to patient's not completing an angiographic or IVUS follow-up procedure. Patients may also have missed the follow-up visits due to early termination from the study.</population>
          <units>percent of in-segment diameter stenosis</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="344"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.77" spread="14.43"/>
                    <measurement group_id="O2" value="22.82" spread="16.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Failure (TVF)</title>
        <description>The composite endpoint comprised of:
Cardiac death (death in which a cardiac cause cannot be excluded)
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI
Ischemia-driven target vessel revascularization (TVR) by CABG or PCI</description>
        <time_frame>5 years</time_frame>
        <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V® EECSS</title>
            <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® EXPRESS2™ ECSS</title>
            <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Failure (TVF)</title>
          <description>The composite endpoint comprised of:
Cardiac death (death in which a cardiac cause cannot be excluded)
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI
Ischemia-driven target vessel revascularization (TVR) by CABG or PCI</description>
          <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="605"/>
                <count group_id="O2" value="286"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.3"/>
                    <measurement group_id="O2" value="26.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Target Lesion Revascularization (ID-TLR)</title>
        <description>Revascularization @ target lesion associated w/ any of following:
(+) functional ischemia study Ischemic symptoms &amp; angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study</description>
        <time_frame>5 years</time_frame>
        <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V® EECSS</title>
            <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® EXPRESS2™ ECSS</title>
            <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Target Lesion Revascularization (ID-TLR)</title>
          <description>Revascularization @ target lesion associated w/ any of following:
(+) functional ischemia study Ischemic symptoms &amp; angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study</description>
          <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="605"/>
                <count group_id="O2" value="286"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9"/>
                    <measurement group_id="O2" value="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Target Vessel Revascularization (ID-TVR)</title>
        <description>Revascularization at the target vessel associated with any of the following
Positive functional ischemia study
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study
Derived from Non-Hierarchical Subject Counts of Adverse Events</description>
        <time_frame>5 years</time_frame>
        <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V® EECSS</title>
            <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® EXPRESS2™ ECSS</title>
            <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Target Vessel Revascularization (ID-TVR)</title>
          <description>Revascularization at the target vessel associated with any of the following
Positive functional ischemia study
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study
Derived from Non-Hierarchical Subject Counts of Adverse Events</description>
          <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="605"/>
                <count group_id="O2" value="286"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8"/>
                    <measurement group_id="O2" value="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Major Adverse Cardiac Event (MACE)</title>
        <description>The composite endpoint comprised of:
Cardiac death
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI</description>
        <time_frame>5 years</time_frame>
        <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V® EECSS</title>
            <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® EXPRESS2™ ECSS</title>
            <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Major Adverse Cardiac Event (MACE)</title>
          <description>The composite endpoint comprised of:
Cardiac death
Myocardial infarction (MI, classified as Q-wave and non-Q wave)
Ischemia-driven target lesion revascularization (TLR) by CABG or PCI</description>
          <population>All patients in the study underwent clinical follow up to provide the information needed for the secondary endpoints. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="605"/>
                <count group_id="O2" value="286"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4"/>
                    <measurement group_id="O2" value="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>XIENCE V® EECSS</title>
          <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
        </group>
        <group group_id="E2">
          <title>TAXUS® EXPRESS2™ ECSS</title>
          <description>TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="219"/>
                <counts group_id="E2" subjects_affected="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 11">Anaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 11">Thrombocytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 11">Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 11">Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 11">Angina pectoris</sub_title>
                <counts group_id="E1" events="51" subjects_affected="42" subjects_at_risk="438"/>
                <counts group_id="E2" events="41" subjects_affected="37" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 11">Angina unstable</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 11">Arrhythmia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="438"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 11">Arteriospasm coronary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 11">Atrial fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 11">Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 11">Atrioventricular block first degree</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 11">Bradycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 11">Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="438"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 11">Cardiorespiratory arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 11">Chest pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 11">Cor pulmonale</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 11">Coronary artery disease</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 11">Coronary artery dissection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 11">Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 11">Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="438"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 11">Coronary artery thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 11">Diastolic dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 11">Instent coronary artery restenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 11">Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="438"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="27" subjects_affected="25" subjects_at_risk="438"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Tachycardia paroxysmal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 10.0">Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="438"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Colonic obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Catheter site haematoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Catheter site haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Hernia obstructive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Noncardiac chest pain</sub_title>
                <counts group_id="E1" events="20" subjects_affected="16" subjects_at_risk="438"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Gallbladder disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Pneumonia fungal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Implantable defibrillator malfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Operative haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Thrombosis in device</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Arteriogram coronary</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Blood pressure decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Cardiac enzymes increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Cardiac stress test abnormal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Compartment syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Thymoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Central nervous system lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Acute psychosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Renal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Physical disability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm repair</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Aortic valve replacement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Atherectomy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Breast lump removal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Cardiac pacemaker replacement</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Carotid artery stent insertion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Carotid endarterectomy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Colectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Coronary angioplasty</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="438"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Coronary arterial stent insertion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Coronary artery bypass graft</sub_title>
                <counts group_id="E1" events="28" subjects_affected="10" subjects_at_risk="438"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Coronary revascularisation</sub_title>
                <counts group_id="E1" events="94" subjects_affected="60" subjects_at_risk="438"/>
                <counts group_id="E2" events="68" subjects_affected="43" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Implantable defibrillator replacement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Prostatectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Renal artery stent placement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Spinal operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Thrombectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Thyroidectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Arterial thrombosis limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Femoral arterial stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 11,0">Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="438"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Iliact artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="438"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Phlebitis superficial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="438"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="71"/>
                <counts group_id="E2" subjects_affected="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="93" subjects_affected="71" subjects_at_risk="438"/>
                <counts group_id="E2" events="44" subjects_affected="35" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="438"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site haematoma</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="438"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ellen Travis, Clinical Science</name_or_title>
      <organization>Abbott Vascular</organization>
      <phone>408-845-1512</phone>
      <email>Ellen.Travis@av.abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

